Nuveen’s Bristol-Myers Squibb BMY Stock Holding History

Nuveen’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-500,000	Closed	-$36K	–	3190
2022 Q3	$36K	Buy	+500,000	New	+$36.3M	﹤0.01%	3174

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nuveen's BMY Position: Q2 2026 in Review

Nuveen reduced its Bristol-Myers Squibb (BMY) stake by 10% in Q2 2026, selling an estimated $34.5M and leaving 5,212,215 shares worth $300M. The position accounts for 0.07% of the portfolio, ranked #204.

Nuveen first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.37B in Q4 2019. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Nuveen held 5,212,215 shares of Bristol-Myers Squibb worth $300M as of Q2 2026.
Nuveen sold 601,418 Bristol-Myers Squibb shares in Q2 2026, an estimated $34.5M.
Bristol-Myers Squibb made up 0.07% of Nuveen's portfolio in Q2 2026, its #204 holding.
Nuveen first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
Nuveen's Bristol-Myers Squibb position peaked at $1.37B in Q4 2019.
2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.